Tag: low-grade glioma market outlook

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Low-Grade Glioma Market Between 2025 And 2029?

The low-grade glioma market size has demonstrated significant expansion in recent years. It is forecast to rise from $1.39 billion in 2024 to $1.47 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.8%. This growth observed in the past can be ascribed to a surge in awareness concerning brain tumors, heightened funding in oncology stimulating research, an increase in orphan drug designations, the broadening reach of telemedicine, and enhanced access to healthcare services.

The market for low-grade glioma is projected to experience substantial expansion in the coming years, with its value anticipated to reach $1.84 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 5.7%. This growth during the forecast period is attributable to several factors, including an expanding aging population, an increase in healthcare spending, the rising occurrence of brain tumors, developing government initiatives, and an uptick in both the incidence and prevalence of high-grade gliomas. Key developments expected within this period encompass advances in imaging technologies, the progression of radiation therapies, the introduction of new chemotherapy regimens, the broadening of clinical trials, and the incorporation of immunotherapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

Which Industry Drivers Are Expected To Accelerate The Low-Grade Glioma Market From 2025 To 2029?

The increasing occurrence of brain tumors is anticipated to boost the growth of the low-grade glioma market moving forward. A brain tumor involves the irregular multiplication of cells within the brain or its surrounding regions, which can be either benign or malignant. The growing incidence of brain tumors stems from factors such as heightened exposure to radiation, environmental contaminants, genetic predispositions, and advancing age. Low-grade glioma proves beneficial for brain tumors through the application of advanced diagnostic tools and targeted treatments like surgery, radiation, and chemotherapy. These methods contribute to slowing tumor progression, preserving neurological function, and enhancing patient outcomes, thus making prompt detection and tailored treatment essential for managing other brain tumors with comparable growth patterns. For example, in October 2023, data from The Central Brain Tumor Registry of the United States (CBTRUS), a US-based not-for-profit organization, indicated that in 2022, the global incidence of primary malignant brain tumors was approximately 3.5 per 100,000. High-income countries reported higher rates at 4.9 per 100,000, in contrast to low-middle and low-income countries, which registered 2.4 per 100,000. Consequently, the rising incidence of brain tumors is propelling the expansion of the low-grade glioma market.

How Is The Low-Grade Glioma Market Classified Into Different Segments?

The low-grade gliomamarket covered in this report is segmented –

1) By Drug Type: Trametinib; Dabrafenib; Ivosidenib; Mirdametinib

2) By Treatment: Surgery; Chemotherapy; Radiation

3) By Route Of Administration: Topical; Oral

4) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies

What Trends Are Redefining The Low-Grade Glioma Market Dynamics?

Key companies within the low-grade glioma market are emphasizing the incorporation of combination therapies and targeted treatments, including genetic alteration drugs, to achieve a competitive advantage and improve care for children with low-grade glioma. These genetic alteration drugs are targeted interventions specifically engineered to modify or suppress particular genetic mutations or cellular abnormalities, thereby aiding in the treatment of conditions like cancer by obstructing mechanisms that promote uncontrolled cell proliferation. An example of this is the launch of Tovorafenib (Ojemda) by Day One Biopharmaceuticals, a US-based biotechnology company, in May 2024, following its accelerated FDA approval. This particular targeted therapy is intended for children six months of age and older who have unresectable or recurrent low-grade glioma (LGG) characterized by BRAF gene alterations. Providing a convenient once-weekly oral administration, it fulfills a significant unmet need for pediatric LGG patients who have had limited previous treatment choices.

Who Are The Prominent Global Companies Shaping The Low-Grade Glioma Market?

Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

What Regional Growth Trends Are Shaping The Low-Grade Glioma Market Outlook?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Low-Grade Glioma Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp

Browse Through More Reports Similar to the Global Low-Grade Glioma Market 2025, By The Business Research Company

Glioma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Adult Malignant Glioma Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Desmoid Tumors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Low-Grade Glioma Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size for low-grade glioma has seen robust growth in the recent past. The market is predicted to expand from $1.39 billion in 2024 to $1.47 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this historic growth include an uptick in brain tumor awareness, a rise in oncology-focused funding to stimulate research, a surge in orphan drug designations, telemedicine proliferation, and increased access to healthcare.

In the ensuing years, the market for low-grade gliomas is projected to experience robust growth, reaching$1.84 billion by 2029 and expanding at a compound annual growth rate (CAGR) of 5.7%. The anticipated growth within this period is linked to the growing elderly population, escalating healthcare spending, a rise in the detection of brain tumors, growing governmental initiatives, and an increment in the occurrence and prevalence of high-grade gliomas. Key trends forecasted in this time frame encompass breakthroughs in imaging technologies, the advancement of radiation therapies, the inception of new chemotherapy protocols, the broadening of clinical trials, and the incorporation of immunotherapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

What External and Internal Drivers Are Contributing to the Growth of theLow-Grade Glioma Market?

The escalating cases of brain tumors are anticipated to drive the expansion of the low-grade glioma market. Brain tumors are unusual cellular growths in the brain or nearby areas, which can either be benign or malignant. The increase in brain tumor cases is attributed to factors like increased radiation exposure, environmental contaminants, genetic susceptibility, and aging. Low-grade glioma assists in managing brain tumors by employing modern diagnostic methods and targeted treatments like surgery, radiation, and chemotherapy. These treatments aid in slowing down the tumor’s growth, preserving neurological functions, and enhancing patient prognosis. Thus, prompt detection and personalized treatment strategies are essential in managing other brain tumors that exhibit similar growth characteristics. As an example, The Central Brain Tumor Registry of the United States (CBTRUS), a US-oriented nonprofit organization, reported in October 2023 that in 2022, the global incidence of primary malignant brain tumors was about 3.5 per 100,000, with higher rates in affluent countries (4.9 per 100,000) than in low-middle (2.4 per 100,000) and low-income countries. Hence, the increasing cases of brain tumors are fueling the growth of the low-grade glioma market.

What Segment Types Define the Low-Grade Glioma Market Structure?

The low-grade gliomamarket covered in this report is segmented –

1) By Drug Type: Trametinib; Dabrafenib; Ivosidenib; Mirdametinib

2) By Treatment: Surgery; Chemotherapy; Radiation

3) By Route Of Administration: Topical; Oral

4) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Low-Grade Glioma Market?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Low-Grade Glioma Market?

The focus of key players in the low-grade glioma market is largely on the incorporation of combined therapies and targeted therapy, including genetic alteration medications, in order to establish a competitive advantage as well as improve treatments for children with low-grade glioma. Drugs that alter genetics are targeted therapies meant to alter or curb specific genetic differences or anomalies in cells, aiding in the treatment of diseases like cancer by halting the avenues that prompt unchecked cell growth. For example, Day One Biopharmaceuticals, a biotech establishment from the US, introduced Tovorafenib (Ojemda) in May 2024, after obtaining fast-tracked approval from the FDA. This therapy, designed for children aged six months and older with non-removable or recurring low-grade glioma (LGG) bearing BRAF gene alterations, is a convenient oral treatment administered once a week. It provides a crucial option for pediatric LGG patients who previously had limited treatment choices.

View the full report here:

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

What Is the Definition of the Low-Grade Glioma Market?

Low-grade gliomas are a type of brain tumor that develops from glial cells, which provide support and insulation to nerve cells in the brain, characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still cause significant neurological symptoms and may require treatments.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21215

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Low-Grade Glioma Market Grown from 2024 to 2025?

In recent years, there has been solid growth in the market size of low-grade glioma. The market is projected to expand from $1.39 billion in 2024 to $1.48 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. The surge in the past period can be linked to enhanced awareness of brain tumors, increased investment in oncology-related research, a rise in the number of designated orphan drugs, the broadening of telemedicine, and improved access to healthcare.

What Growth Rate Is Anticipated for the Low-Grade Glioma Market in the Coming Years?

The market for low-grade gliomas is projected to experience significant expansion in the coming years, becoming a staggering $1.86 billion industry by the year 2029 with a Compound Annual Growth Rate (CAGR) of 5.9%. This anticipated growth through the forecast period is likely due to demographic shifts toward an older population, increasing healthcare expenses, a higher frequency of brain tumors, proliferating governmental initiatives, and a surge in instances and prevalence of high-grade gliomas. Notable market trends in the forecast period encompass progress in imaging technologies, the development and introduction of radiation treatments and chemotherapy regimens, increased clinical trial activity, and the inclusion of immunotherapy.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

Who Are the Leading Companies in the Low-Grade Glioma Market?

Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.

What Are the Key Drivers of the Low-Grade Glioma Market?

The upward trend in brain tumor occurrences is anticipated to stimulate the expansion of the low-grade glioma market. Brain tumors, a growth of abnormal cells in the brain or adjacent areas, can either be harmless or malignant. This surge in brain tumor incidences could be attributed to factors such as heightened exposure to radiation, environmental toxins, genetic predisposition, and aging. Low-grade glioma serves as a beneficial tool in brain tumor treatment primarily utilizing avant-garde diagnostic methods and specific treatments such as surgery, radiation and chemotherapy. These techniques aid in decelerating tumor progression, conserving neurological function, and enhancing patient outcomes thereby emphasizing the importance of early detection and personalized treatment in managing other brain tumors exhibiting similar growth behaviours. For instance, as per The Central Brain Tumor Registry of the United States (CBTRUS) – a non-profit organization based in the US, in October 2023, it was reported that in 2022, the global incidence rate of primary malignant brain tumors was roughly 3.5 per 100,000, with elevated rates in high-income countries (4.9 per 100,000) as opposed to low-middle (2.4 per 100,000) and low-income countries. Consequently, the escalating incidences of brain tumors are propelling the expansion of the low-grade glioma market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp

What Are the Key Market Segments in the Low-Grade Glioma Industry?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Route Of Administration: Topical, Oral

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

What Are the Latest Trends in the Low-Grade Glioma Market?

Top-tier corporations in the low-grade glioma industry are leveraging the merger of combination therapies and targeted remedies, such as drugs altering genetic composition, to consolidate their market stand and improve treatment procedures for pediatric patients with low-grade glioma. Genetic alteration medications serve as targeted remedies intended to change or suppress specific genetic irregularities or mutations in cells, thereby aiding in treating conditions like cancer by obstructing the routes that fuel unchecked cell multiplication. For example, in May 2024, Day One Biopharmaceuticals, a biotech organization based in the United States, unveiled Tovorafenib (Ojemda) following express FDA approval. This target-based treatment is meant for children aged six months and above diagnosed with inoperable or recurrent low-grade glioma (LGG) having BRAF gene alterations. Offering an adaptable single-weekly oral therapy, it responds to an essential need for pediatric LGG patients with previously limited treatment choices.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

What Are the Key Regional Markets in the Low-Grade Glioma Industry?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21215

This Report Delivers Insight On:

1. How big is the low-grade glioma market, and how is it changing globally?

2. Who are the major companies in the low-grade glioma market, and how are they performing?

3. What are the key opportunities and risks in the low-grade glioma market right now?

4. Which products or customer segments are growing the most in the low-grade glioma market?

5. What factors are helping or slowing down the growth of the low-grade glioma market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What is the Projected CAGR for the Low-Grade Glioma Market Size from 2025 to 2034?

In recent years, there has been significant growth in the market size of low-grade glioma. An increase from $1.39 billion in 2024 to $1.48 billion in 2025 is projected, implying a compound annual growth rate (CAGR) of 6.1%. The growth witnessed in the past can be credited to the heightened awareness of brain tumors, the rise in oncology-centered funding which promotes research, the surge in the designation of orphan drugs, the broadening scope of telemedicine, and heightened healthcare accessibility.

Expectations are high for a robust expansion of the low-grade glioma market in the coming years. The market’s projected rise to $1.86 billion in 2029, representing a compound annual growth rate (CAGR) of 5.9%, signals this. A number of factors will contribute to this growth over the forecast period including an increase in the elderly population, heightened spending on healthcare, a surge in brain tumor cases, escalating government interventions, and an uptick in the incidence and prevalence of high-grade gliomas. The prediction period will also see significant trends such as advancements in imaging technologies, the evolution of radiation therapies, debut of new chemotherapy regimens, proliferation of clinical trials, and the inclusion of immunotherapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

What are the Fundamental Drivers and Innovations Shaping the Low-Grade Glioma Market?

The surge in brain tumor cases is anticipated to spur the expansion of the low-grade glioma market in the future. Brain tumors, categorized as benign or malignant, emerge from unusual cell growth in the brain or its nearby regions. Exposure to radiation, environmental contaminants, genetic susceptibility, and aging are primary factors contributing to the rising incidence of brain tumors. Low-grade glioma plays a crucial role in treating brain tumors by employing innovative diagnostic methods and specific therapies including surgery, radiation, and chemotherapy. These methods slow tumor growth, conserve neurological function, and enhance patient outcomes, underscoring the importance of early detection and individualized treatment in managing other brain tumors with similar growth patterns. For example, in 2023, The Central Brain Tumor Registry of the United States (CBTRUS), reported that the global incidence rate of primary malignant brain tumors in 2022 was about 3.5 per 100,000. The prevalence was higher in high-income countries (4.9 per 100,000) compared to middle-low income (2.4 per 100,000) and low-income countries. As a result of the increasing incidence of brain tumors, there has been substantial growth in the low-grade glioma market.

How Is the Low-Grade Glioma Market Segmented?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Route Of Administration: Topical, Oral

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp

Which Regions Are Driving the Next Phase of the Low-Grade Glioma Market Growth?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Low-Grade Glioma Market?

Leading corporations in the low-grade glioma market are now directing their focus towards the incorporation of both combination therapies and targeted treatment, including drugs tailored to genetic alterations, with the goal of maintaining their competitiveness and improving treatment options for children suffering from low-grade glioma. Drugs designed to alter genetics are targeted treatments created to either modify or suppress specific genetic mutations or cell abnormalities, thus effectively treating illnesses such as cancer by halting the mechanisms that trigger unchecked cell growth. For example, in May 2024, Day One Biopharmaceuticals, a firm based in the United States, introduced Tovorafenib (Ojemda) after receiving accelerated approval from the FDA. Formulated to cater to children who are at least six months old and who have unresectable or recurring low-grade glioma (LGG) with BRAF gene alterations, this targeted treatment offers a convenient weekly oral medication, thus meeting a critical need for pediatric LGG patients who had fewer prior treatment choices.

View the full report here:

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

How Is the Low-Grade Glioma Market Defined and What Are Its Core Parameters?

Low-grade gliomas are a type of brain tumor that develops from glial cells, which provide support and insulation to nerve cells in the brain, characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still cause significant neurological symptoms and may require treatments.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21215

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the low-grade glioma market grown in recent years?

In recent times, the market size of low-grade glioma has experienced substantial growth. It’s projected to increase from its size of $1.39 billion in 2024 to $1.48 billion in 2025, displaying a compound annual growth rate (CAGR) of 6.1%. This evolutionary growth during the historic period can be credited to factors such as heightened awareness about brain tumors, a rise in oncology research funding, a surge in the designation of orphan drugs, the broadening of telemedicine, and improved access to healthcare.

How is the low-grade glioma market size expected to evolve during the forecast period?

The market size of low-grade glioma is predicted to exhibit substantial growth in the forthcoming years, reaching a valuation of $1.86 billion in 2029 with a compound annual growth rate (CAGR) of 5.9%. The surge during the forecast period is primarily due to factors such as an increase in the elderly population, surge in healthcare spending, escalating cases of brain tumors, growth in government-led initiatives, and a rise in the occurrence and prevalence of high-grade gliomas. Key trends during the forecast period consist of improvements in imaging technologies, advancements in radiation therapies, the advent of chemotherapy regimens, the expansion of clinical trials, and the integration of immunotherapy.

Get your low-grade glioma market report here!

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

Which key drivers are propelling the low-grade glioma market’s growth?

The upsurge in occurrences of brain tumors is anticipated to boost the development of the low-grade glioma market in the future. Brain tumors are abnormal cell growths that can appear in the brain or nearby regions and can be benign or malignant. Factors such as increased radiation exposure, environmental pollutants, genetic susceptibilities, and aging contribute to the increasing brain tumor incidence. Low-grade gliomas effectively manage brain tumors by using state-of-the-art diagnostic methods and target-based treatments such as surgery, radiation, and chemotherapy, thus slowing tumor growth, maintaining neurological functions, and enhancing patient results. It is therefore essential to detect promptly and customize treatments for other brain tumors mirroring similar growth trends. The Central Brain Tumor Registry of the United States (CBTRUS), a non-profit organization based in the US, stated in October 2023 that in 2022, the global incidence rate of primary malignant brain tumors was roughly 3.5 per 100,000. Rates were high in high-income countries (4.9 per 100,000) compared to low-middle (2.4 per 100,000) and low-income countries. The escalating incidence of brain tumors, consequently, is propelling the advancement of the low-grade glioma market.

What are the market segments in the low-grade glioma industry?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Route Of Administration: Topical, Oral

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

Which leading companies are shaping the growth of the low-grade glioma market?

Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.

How are evolving market trends shaping low-grade glioma Strategies?

Key businesses in the low-grade glioma market are concentrating their efforts on incorporating combination therapies and targeted treatments, such as genetic modification drugs, in order to maintain a competitive advantage and improve the care for children suffering from low-grade glioma. Genetic modification drugs are a type of targeted treatment that aim to change or inhibit specific gene mutations or irregularities within cells. These drugs aim to treat illnesses like cancer by interfering with the processes that instigate unchecked cell growth. For example, Day One Biopharmaceuticals, a biotech company based in the US, launched Tovorafenib (Ojemda) in May 2024, following fast-tracked FDA approval. This targeted therapy is created for children aged six months or older with inoperable or recurrent low-grade glioma (LGG) with BRAF gene alterations. The once-weekly oral treatment offers convenience and addresses an important need for pediatric LGG patients who had previously limited treatment choices.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21215

Which geographic areas are influencing the growth of the low-grade glioma market?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Infertility Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/infertility-treatment-global-market-report

Fertility Treatments Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report

Urinary Tract Infection Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/urinary-tract-infection-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Anticipated CAGR of the Low-Grade Glioma Market, and What Factors Will Drive It?

In recent times, a robust expansion has been observed in the market for low-grade glioma. The market, which stood at $1.39 billion in 2024, is forecasted to grow to $1.48 billion by 2025, with a compound annual growth rate (CAGR) of 6.1%. The factors driving this noticeable growth during the historic period include a heightened awareness about brain tumors, more investment in oncology-driven research, increased allocations for orphan drug designation, advancement in telemedicine, and the enhancement of healthcare access.

In the coming years, the market for low-grade glioma is projected to experience robust growth. With a compound annual growth rate (CAGR) of 5.9%, the market is anticipated to reach $1.86 billion by 2029. The growth during this projection period can be linked to factors such as an increasing aging population, rising spending on healthcare, growth in the incidence of brain tumors, government initiatives, and an upswing in both the incidence and prevalence of high-grade gliomas. Significant trends expected within this forecast period encompass improvements in imaging technologies, the evolution of radiation therapies, the launch of new chemotherapy regimens, expansion of clinical trials, and the addition of immunotherapy.

What Drivers Are Shaping the Growth of the Low-Grade Glioma Market?

Expected growth in the low-grade glioma market is largely due to the surge in brain tumor incidents. Brain tumors are an unusual aggregation of cells in the brain or its neighboring areas and can be benign or malignant. Factors such as heightened exposure to radiation, environmental toxins, genetic predisposition, and aging contribute to the increased occurrence of brain tumors. Low-grade glioma helps manage the said tumors, employing advanced diagnostic techniques and specialized treatments including but not limited to surgery, radiation, and chemotherapy. These treatments help control tumor progression, uphold neurological functionality, and enhance patient outcomes, stressing the importance of early detection and tailored treatment for curbing other brain tumors with similar growth habits. As an example, The Central Brain Tumor Registry of the United States (CBTRUS), a non-profit organization based in the US, reported in October 2023 that the global rate of primary malignant brain tumors in 2022 was roughly 3.5 per 100,000. It was noted that high-income countries had a higher rate (4.9 per 100,000) compared to low-middle (2.4 per 100,000) and low-income countries. Hence, this surge in brain tumor incidents is prompting the expansion of the low-grade glioma market.

Explore Comprehensive Insights Into The Global Low-Grade Glioma Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp

Who Are the Top Companies Contributing to the Growth of the Low-Grade Glioma Market?

Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.

How Are Technological Trends Affecting the Growth and Development of the Low-Grade Glioma Market?

Leading businesses in the low-grade glioma market are integrating combination therapy and targeted therapy, such as drugs for genetic alterations, to solidify their market presence and improve treatments for children affected by low-grade glioma. These genetic alteration medicines are targeted treatments aimed to regulate or suppress certain gene mutations or irregularities in cells. This aids in the treatment of diseases like cancer by restricting the routes that facilitate the uncontrollable growth of cells. For example, Day One Biopharmaceuticals, an American biotech firm, launched Tovorafenib (Ojemda) in May 2024 after obtaining fast-tracked FDA approval. This targeted treatment is meant for children aged six months and above with inoperable or recurring low-grade glioma (LGG) accompanied by BRAF gene modifications. With a convenient oral intake once a week, it caters to the crucial needs of pediatric LGG patients who previously had limited treatment alternatives.

Secure Your Global Low-Grade Glioma Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report

Which Segments of the Low-Grade Glioma Market Hold the Most Potential for Future Development?

The low-grade glioma market covered in this report is segmented –

1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib

2) By Treatment: Surgery, Chemotherapy, Radiation

3) By Route Of Administration: Topical, Oral

4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

What Are the Key Regions Powering Growth in the Low-Grade Glioma Market?

North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Defines the Scope of the Low-Grade Glioma Market?

Low-grade gliomas are a type of brain tumor that develops from glial cells, which provide support and insulation to nerve cells in the brain, characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still cause significant neurological symptoms and may require treatments.

Browse Through More Similar Reports By The Business Research Company:

Infertility Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/infertility-treatment-global-market-report

Fertility Treatments Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report

Urinary Tract Infection Treatment Global Market Report 2025

https://thebusinessresearchcompany.com/report/urinary-tract-infection-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: